Results 21 to 30 of about 10,699 (192)

Eosinophil Apoptosis and Clearance in Asthma [PDF]

, 2013
Peer reviewedPublisher ...
Bickham U.R., Duval E., Fadok V.A., Fadok V.A., Gaipl U.S., Hart S.P., Luttmann W., Meagher L.C., Schwartz B.R., Walsh G.M.   +9 more
core   +3 more sources

Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein–protein interaction analyses

Respiratory Research, 2023
Introduction Biomarkers are needed to inform the choice of biologic therapy in patients with asthma given the increasing number of biologics. We aimed to identify proteins associated with response to omalizumab and mepolizumab.
Ayobami Akenroye, Tanawin Nopsopon, Laura Cho, Matthew Moll, Scott T. Weiss   +4 more
doaj   +1 more source

Recovery of smell sense loss by mepolizumab in a patient allergic to dermatophagoides and affected by chronic rhinosinusitis with nasal polyps [PDF]

, 2019
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently presents with dysfunction or loss of the sense of smell, resulting in a signifcant impairment in quality of life.
Cavaliere, Carlo, Ciotti, Mario, de Vincentiis, Marco, Frati, Franco, Greco, Antonio, Incorvaia, Cristoforo, Masieri, Simonetta, Messineo, Daniela   +7 more
core   +1 more source

A systematic review and integrated analysis of biologics that target Type 2 inflammation to treat COPD with increased peripheral blood eosinophils

Heliyon, 2022
Background and aims: Biologics that target Type 2 inflammation are effective in reducing exacerbations of severe asthma. We conducted a systematic review and integrated analysis of the efficacy and safety of these biologics in chronic obstructive ...
Hiroshi Ohnishi, Masamitsu Eitoku, Akihito Yokoyama   +2 more
doaj   +1 more source

Churg-Strauss Syndrome with Necrosis of Toe Tips [PDF]

, 2011
Churg-Strauss syndrome (CSS) is a granulomatous necrotizing vasculitis of unknown etiology associated with bronchial asthma. Despite affecting small to medium-sized vessels, necrosis of the digits due to vasculitis is extremely rare.
Hasegawa, Kenjiro, Ikeda, Genyo, Kanehiro, Arihiko, Kimata, Yoshihiro, Miyahara, Nobuaki, Nojima, Daisuke, Okada, Chiharu, Tanimoto, Mitsune, Tanimoto, Yasushi, Waseda, Koichi   +9 more
core   +1 more source

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab

Respiratory Medicine Case Reports, 2019
We described three severe asthmatics whose asthma symptoms were rapidly improved by benralizumab following favorable response to mepolizumab. Benralizumab-induced eosinophil depletion contributed to clinical improvement of severe asthma after mepolizumab-
Osamu Matsuno, Seijiro Minamoto
doaj   +1 more source

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts

Allergy, Asthma & Clinical Immunology, 2021
Background Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on
Arian Ghassemian, Jane Jiyoon Park, Michael W. Tsoulis, Harold Kim   +3 more
doaj   +1 more source

Monoclonal antibodies in type 2 asthma : a systematic review and network meta-analysis [PDF]

, 2019
Since novel treatments to target eosinophilic inflammation in Type 2 asthma are emerging, we aimed to evaluate and meta-analyze the efficacy of monoclonal antibodies to reduce exacerbation rate.
De Feyter, Silke, Edris Mohamed, Ahmed, Joos, Guy, Lahousse, Lies, Maes, Tania   +4 more
core   +1 more source

Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma : results from two phase 3, randomised, double-blind, placebo-controlled trials [PDF]

, 2020
BACKGROUND: Reslizumab 3 mg/kg administered intravenously is approved for the treatment of severe eosinophilic asthma. We assessed the safety and efficacy of subcutaneous reslizumab 110 mg in two trials in patients with uncontrolled severe asthma and ...
Adir, Yochai, Bernstein, Jonathan A, Brusselle, Guy, Castro, Mario, Garin, Margaret, Hickey, Lisa, Humbert, Marc, Jacobs, Joshua, Marsteller, Douglas A, Maspero, Jorge Fernando, McElhattan, Jennifer, Murphy, Kevin, Vanlandingham, Rebecca, Virchow, J Christian   +13 more
core   +1 more source

Characteristics of new adult users of mepolizumab with asthma in the USA

BMJ Open Respiratory Research, 2021
Background In the USA, over 25 million people have asthma; 5%–10% of cases are severe. Mepolizumab (Nucala) is an interleukin-5 antagonist monoclonal antibody; it was approved by the FDA in 2015 as add-on maintenance treatment of severe asthma for ...
Pamela M McMahon, Ann Chen Wu, Emily Welch, Cheryl N McMahill-Walraven, Aziza Jamal-Allial, Mia Gallagher, Tancy Zhang, Christine Draper, Anne Marie Kline, Leslie Koerner, Jeffrey S Brown, Melissa K Van Dyke   +11 more
doaj   +1 more source